Emergent BioSolutions Inc. (EBS) 의 후행 P/E는 8.5, 선행 P/E 16.7. 후행 이익수익률은 11.83%, 선행 이익수익률 6.01%. PEG 0.83 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $14.70.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 53/100 2/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 25.5 | -1.22 | 2.21 | 2.70 | - |
| 2017 | 23.5 | 0.44 | 2.13 | 3.46 | - |
| 2018 | 47.4 | -1.28 | 2.94 | 3.80 | - |
| 2019 | 51.0 | -3.35 | 2.55 | 2.51 | - |
| 2020 | 15.4 | 0.03 | 3.26 | 2.99 | - |
| 2021 | 10.6 | -0.36 | 1.44 | 1.31 | - |
| 2022 | -2.8 | 0.01 | 0.43 | 0.53 | - |
| 2023 | -0.2 | 0.00 | 0.19 | 0.12 | - |
| 2024 | -2.7 | 0.04 | 1.05 | 0.49 | - |
| 2025 | 12.6 | -0.10 | 1.27 | 0.89 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $1.13 | $488.78M | $51.78M | 10.6% |
| 2017 | $1.71 | $560.87M | $82.59M | 14.7% |
| 2018 | $1.22 | $782.4M | $62.7M | 8% |
| 2019 | $1.04 | $1.11B | $54.5M | 4.9% |
| 2020 | $5.67 | $1.56B | $305.8M | 19.7% |
| 2021 | $4.06 | $1.79B | $219.5M | 12.2% |
| 2022 | $-4.47 | $1.12B | $-223.8M | -20% |
| 2023 | $-14.85 | $1.05B | $-760.5M | -72.5% |
| 2024 | $-3.60 | $1.01B | $-190.6M | -18.8% |
| 2025 | $0.93 | $742.9M | $52.6M | 7.1% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $0.52 | $0.52 – $0.52 | $745M | $743.67M – $746.33M | 1 |
| 2027 | $-0.96 | $-0.96 – $-0.96 | $892M | $890.41M – $893.59M | 1 |
| 2028 | $0.43 | $0.43 – $0.43 | $878.6M | $877.03M – $880.17M | 1 |
| 2029 | $0.90 | $0.90 – $0.90 | $963.2M | $961.48M – $964.92M | 1 |
